Latest News, Updates & Breaking Headlines
Pfizer is poised to acquire US-based biotechnology firm Metsera in a $10 billion deal, after winning a heated bidding battle against Danish drugmaker Novo Nordisk, which has now withdrawn from the race, AFP reported.Metsera, which specialises in obesity treatments, said in a statement that Pfizer’s improved offer of $86.25 per share had been unanimously approved…
Danish pharmaceutical giant Novo Nordisk, the maker of obesity drugs Ozempic and Wegovy, lowered its 2025 sales outlook for the fourth time this year on Wednesday after reporting tepid third-quarter results.The company, which appointed Mike Doustdar as CEO in August, now expects full-year sales growth of 8 to 11 per cent, down from a previous…
Drug giants Novo Nordisk and Pfizer are locked in a fierce $9 billion bidding war for obesity drug developer Metsera. Novo’s unsolicited offer challenges Pfizer’s earlier $7.3 billion deal, highlighting the immense value and competition in the booming weight-loss drug market. This corporate showdown could redefine the future of obesity treatment. Novo Nordisk, the Danish…
Denmark’s Novo Nordisk, the pharmaceutical giant behind blockbuster drugs Ozempic and Wegovy, is set for a major boardroom shake-up amid internal disagreements and growing competitive pressure in the weight-loss drug market. The company on Tuesday announced that it will replace more than half of its 12-member board, including its chair, following a dispute with its…
Tata 1mg seeks $200 mn funding Tata 1mg, the online pharmacy arm of Tata Digital, is looking to raise $200 million in a fresh funding round, attracting interest from Novo Holdings, Canadian pension fund CPPIB, Permira, and Chrys Capital, according to sources familiar with the matter.The fundraising is part of a larger capital raise across…
